GlaxoSmithKline and POZEN Inc announced that the drug Trexima will be reviewed by the FDA for the acute treatment of migraine headaches. The companies have proposed Trexima as the brand name for their combination of sumatriptan succinate (Imitrex) and naproxen sodium (Aleve, for example) in a single-tablet form. Pending approval by the FDA, Trexima could be available to the public by the second half of 2006.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs